Trial document




This trial has been registered retrospectively.
drksid header

  DRKS00009819

Trial Description

start of 1:1-Block title

Title

Validating genomic biomarkers as risk markers for incidence, non-response and recurrence in depression - CAP Study

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

OptiMD-SP4 CAP

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

Preliminary own work and findings of our partners point to a special significance of the blood-brain barrier gene ABCB1, the stress regulation gene FKBP5 and so-called "Gliotransmitter" genes P2RX4 and P2RX7 with respect to depression risk and antidepressant treatment outcome. Genomic indicators of the activity of these genes and their epigenetic modifications are promising candidates for serving as genomic biomarkers of depression, which will be validated in this program. There are three subprojects. The subproject considered here is called CAP study aiming to validate epigenetic biomarkers in regard to the risk of developing depression. A case/control study with 100 adolescents will be carried out, half of them suffering from depression (cases), while the other half will be negative for psychiatric disorders (controls). Saliva samples will be collected from both groups to obtain DNA. In addition, chemical modifications of the DNA (so-called epigenetic modifications) will be measured, which, unlike DNA, can be affected by environmental conditions and thereby might additionally contribute to the disease risk. We expect that both, genetic variations and epigenetic DNA modifications ciontribute to the disease risk. The aim of subproject is to identify those characteristics and to determine their contribution to the disease risk.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

To validate epigenetic biomarkers for the disease risk of depression we are recruiting 50 adolescents with and 50 adolescents without diagnosis of acute depression for a case/control study. Clinical diagnosis will be optained using the Diagnostic Interview for Mental Disorders in Children and Adolescents (Kinder-DIPS). DNA will be extracted from saliva samples, genotyped and methylation rates of CpG-rich regions will be analyzed and compared between cases and controls. In particular, methylation rates of the following candidate genes are in the center of the analysis: ABCB1, FKBP5, P2RX4, P2RX5.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00009819
  •   2016/01/13
  •   [---]*
  •   yes
  •   Approved
  •   419-15, Ethik-Kommission der Medizinischen Fakultät der Ludwig-Maximilians-Universität München
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  • [---]*
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   F32 -  Depressive episode
  •   F33 -  Recurrent depressive disorder
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Case/Control study comparing epigenetic modifications (DNA methylation) in CpG-rich regions within candidate genes (ABCB1, FKBP5, P2RX4, P2RX5) between adolescents with and without diagnosis of major depression.
    DNA will be extracted from saliva samples, genotyped and methylation rates of CpG-rich regions will be analyzed and compared between cases and controls.
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Non-interventional
  •   Other
  •   Single arm study
  •   Open (masking not used)
  •   [---]*
  •   Uncontrolled/Single arm
  •   Diagnostic
  •   Single (group)
  •   N/A
  •   N/A
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Case or control group assignment based on a detailed diagnosis using the Diagnostic Interview for Mental Disorders in Children and Adolescents (Kinder-DIPS). Genetic variations and DNA methylation rates in CpG-rich regions of the genes ABCB1, FKBP5, P2RX4 and P2RX7 will be determined as predictors of the case/control status.

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

N.A.

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • University Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Actual
  •   2015/09/01
  •   100
  •   Monocenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   8   Years
  •   18   Years
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

Children and adolescents of both sexes aged 8 to 18 years, balanced in age and sex distribution between cases and controls; study consent of at least one parent or guardian of the study participant as well as oral and / or written consent of the minor study participant.

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

Pervasive developmental disorder in study participants (ICD10 F84)

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Max-Planck-Institut für Psychiatrie
    • Mr.  Dr.  Marcus  Ising 
    • Kraepelinstr. 2-10
    • 80804  München
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address other
    • Klinikum der UniversitätInstitut für Kinder- und Jugendpsychiatrie
    • Mr.  Prof. Dr.  Gerd  Schulte-Körne 
    • Nußbaumstr. 5a
    • 80337  München
    • Germany
    end of 1:1-Block address other
    start of 1:1-Block address contact other
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact other
  • start of 1:1-Block address scientific-contact
    • Klinikum der UniversitätInstitut für Kinder- und Jugendpsychiatrie
    • Mr.  Prof. Dr.  Gerd  Schulte-Körne 
    • Nußbaumstr. 5a
    • 80337  München
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Klinikum der UniversitätInstitut für Kinder- und Jugendpsychiatrie
    • Mr.  Prof. Dr.  Gerd  Schulte-Körne 
    • Nußbaumstr. 5a
    • 80337  München
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Bundesministerium für Bildung und Forschung Dienstsitz Bonn
    • Heinemannstr. 2
    • 53175  Bonn
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting ongoing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.